In a late-stage trial, GSK’s experimental medicine achieved its main objective of lowering asthma episodes, providing hope for a therapy that the British pharmaceutical anticipates would reach peak annual sales of 3 billion pounds ($3.81 billion).

According to GSK, the medication known as depemokimab shown “significant and meaningful reductions” in the frequency of asthma episodes in those with eosinophilic asthma on Tuesday.

Elevations of the white blood cell called eosinophils are a defining feature of this kind of asthma.

The outcomes coincide with GSK’s increased emphasis on its respiratory health portfolio, which is flourishing at the moment due to the successful introduction of its Arexvy respiratory syncytial virus (RSV) vaccine.

Earlier this year, the business also paid up to $1.4 billion to acquire Aiolos Bio, a manufacturer of asthma medications.

Depemokimab, which has the potential to be a significant growth driver by the end of the decade, is one of the 12 big releases that GSK is preparing for, beginning in 2025.

According to GSK, the medication may be the first ultra-long-acting biologic that is authorised and has a six-month dosage regimen for patients with severe asthma.

“Discovered by our scientists in Stevenage, Depemokimab builds on our deep heritage and leadership in respiratory medicine and has the potential to make a real difference to the millions of people whose lives are affected every day by severe asthma,” said Tony Wood, GSK’s chief scientific officer.

(Adapted from DeccanHerald.com)